A Robust HPLC Method for the Simultaneous Determination of Finerenone and Its Enantiomer Using AQbD.
Sign Up to like & getrecommendations! Published in 2025 at "Chirality"
DOI: 10.1002/chir.70052
Abstract: The enantiomeric purity of Finerenone (FIN), a novel therapeutic for chronic kidney disease (CKD), is a critical quality attribute for ensuring patient safety. This study reports the first chiral HPLC method for the simultaneous determination… read more here.
Keywords: enantiomer; method; hplc method; finerenone ... See more keywords
Cardiovascular Efficacy and Safety of Finerenone: A Meta‐Analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cardiology"
DOI: 10.1002/clc.70065
Abstract: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a novel therapeutic option for the management of patients with diabetes, chronic kidney disease, or heart failure. We seek to summarize the evidence on the drug's… read more here.
Keywords: meta analysis; finerenone meta; safety finerenone; finerenone ... See more keywords
Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13219
Abstract: In post‐menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits. We tested whether the non‐steroidal mineralocorticoid receptor antagonist finerenone limits the progression… read more here.
Keywords: heart; receptor blockade; heart failure; mineralocorticoid receptor ... See more keywords
Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry
Sign Up to like & getrecommendations! Published in 2025 at "ESC Heart Failure"
DOI: 10.1002/ehf2.15260
Abstract: Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline… read more here.
Keywords: finerenone patients; patients heart; finerenone; heart failure ... See more keywords
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2019 at "Heart Failure Reviews"
DOI: 10.1007/s10741-019-09790-5
Abstract: The efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure (HF) are controversial. To explore the role of MRAs in HF patients with an ejection fraction of no more than 45%,… read more here.
Keywords: sucra; efficacy safety; heart failure; finerenone ... See more keywords
The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment
Sign Up to like & getrecommendations! Published in 2025 at "Heart Failure Reviews"
DOI: 10.1007/s10741-025-10520-3
Abstract: The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone is indicated in the United States for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Results from the FIDELIO-DKD and FIGARO-DKD Phase… read more here.
Keywords: chronic kidney; finerenone; heart failure;
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
Sign Up to like & getrecommendations! Published in 2020 at "Current Cardiology Reports"
DOI: 10.1007/s11886-020-01399-7
Abstract: We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently… read more here.
Keywords: mineralocorticoid receptor; review; finerenone; receptor ... See more keywords
Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer Perspective
Sign Up to like & getrecommendations! Published in 2024 at "Advances in Therapy"
DOI: 10.1007/s12325-024-03084-5
Abstract: Type 2 diabetes (T2D) is a major cause of chronic kidney disease (CKD) in Japan, and there is an increasing treatment need for first- and second-line care in these patients. The addition of finerenone to… read more here.
Keywords: treatment; finerenone; payer perspective; cost ... See more keywords
Finerenone: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01599-7
Abstract: Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF).… read more here.
Keywords: first approval; disease; finerenone; finerenone first ... See more keywords
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Sign Up to like & getrecommendations! Published in 2024 at "Nature Medicine"
DOI: 10.1038/s41591-024-03264-4
Abstract: Cardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease and diabetes. The non-steroidal mineralocorticoid receptor antagonist finerenone has been studied in three prospective randomized clinical trials of patients with cardiovascular-kidney-metabolic syndrome:… read more here.
Keywords: pooled analysis; heart; finerenone; cardiovascular kidney ... See more keywords
The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical science"
DOI: 10.1042/cs20220212
Abstract: Despite strong preclinical data supporting the use of mineralocorticoid receptor antagonists (MRAs) to provide cardiorenal protection in rodent models of diabetes, the clinical evidence of their utility in treating chronic kidney disease (CKD) has been… read more here.
Keywords: kidney; chronic kidney; finerenone; type diabetes ... See more keywords